Jerusalem, 18 November, 2026 (TPS-IL) — An Israeli medical technology company has received a U.S. regulatory boost for its test to detect a treatable brain condition often mistaken for Alzheimer’s disease. Haifa-based Biostream said Wednesday that the U.S. Food and Drug Administration granted Breakthrough Device Designation to its urine test for normal pressure hydrocephalus, which can cause walking difficulties, memory problems and loss of bladder control.

The test analyzes proteins in urine using a proprietary algorithm to help distinguish the condition from Alzheimer’s and other neurological disorders. The designation provides priority FDA review but does not constitute approval. Biostream plans a clinical validation study at U.S. academic medical centers in 2027.